Geron Corporation Share Price

Geron Corporation Share Price

NASDAQ: GERN | Small Cap
$0.95
-$0.02 (-2.29%) Last updated on 30 Oct, 2026 | 01:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Geron Corporation Stock Performance

Open
$0.98
Prev. Close
$0.97
Circuit Range
N/A
Day Range
$0.91 - $1.01
Year Range
$0.84 - $2.00
Volume
7,19,544
Average Traded
$0.96

Geron Corporation Share Price Today

As of 30 October 2026, Geron Corporation's share price is $0.95. The stock opened at $0.98, compared to its previous close of $0.97. During today's trading session, Geron Corporation's share price traded between $0.91 and $1.01, with an average price of $0.96. Over the past 52 weeks, the stock has recorded a high of $2.00 and a low of $0.84. In terms of performance, Geron Corporation's share price has declined by 38.76% over the last six months and is down 24.90% on a year-on-year basis.

Geron Corporation Share Price Chart

Line chart of the Geron Corporation price trend over the selected period. The price fell overall, ranging from 0.91 to 1.01, ending at 0.95.
$0.91$1.01
L
Show Current Price
H

Geron Corporation Stock Fundamentals & Key Indicators

Market Cap
$630.80M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.11
Revenue (TTM)
$183.88B
Return On Equity (TTM)
-30.93%
Profit Margin
-45.41%
Debt to Equity
1.14
Quarterly Earnings Growth YoY
9.50%

Geron Corporation Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$47.23$48.02$51.84$57.48
Net Profit-$18.43-$28.86-$3.64-$16.68
Net Profit Margin-39.02%-60.10%-7.02%-29.02%
Income ChangeN/A-56.59%87.39%-358.24%

Geron Corporation Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.60$0.24$76.99$183.88
Net Profit-$141.90-$184.13-$174.57-$83.50
Net Profit Margin-23650.00%-76720.83%-226.74%-45.41%
Income ChangeN/A-29.76%5.19%52.17%

About Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Geron Corporation Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$1.24
$0.95
-23.40%
Sep 2026
$1.49
$1.24
-19.02%
Aug 2026
$1.27
$1.52
+17.76%
Jul 2026
$1.29
$1.29
+1.17%
Jun 2026
$1.25
$1.28
+3.23%
May 2026
$1.54
$1.24
-19.74%
Apr 2026
$1.52
$1.54
+4.04%
Mar 2026
$1.60
$1.49
-11.61%
Feb 2026
$1.35
$1.68
+23.53%
Jan 2026
$1.33
$1.36
+2.64%
Dec 2025
$1.16
$1.32
+12.29%
Nov 2025
$1.27
$1.18
-6.35%

GERN Share Price FAQs